MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma. The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial. TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform. It is… Read More
A world-first clinical trial is launching to test an experimental vaccine designed to prevent lung cancer in people at high risk of the disease. Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. Researchers… Read More
A nanoparticle-based vaccine developed by the University of Massachussets Amherst could effectively prevent melanoma, pancreatic and triple-negative breast cancer, the university reveals. Scientists tested the vaccine in mice, with 88% remaining tumour-free. The results also show that the vaccine reduced, and in some cases prevented, the spread… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen some incredible advances in immunotherapy, including the development of a therapy… Read More
News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner. This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one… Read More
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer. The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on… Read More
News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. The top stories:… Read More
GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and… Read More
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More
News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for… Read More
The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study. The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More
Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine… Read More
Infinitopes presented three posters on its cancer vaccine discovery and development strategy, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10 November. A spinout from Oxford University, supported by Cancer Research UK (CRUK),… Read More
